Xeris Biopharma Holdings Inc (XERS) returns
Xeris Biopharma returns over 5 years
$1,000 invested in Xeris Biopharma five years ago was worth $5,758 at the close on October 30, 2026, with dividends reinvested: an average return of 41.9% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | +12.0% | — | $1,120 | -0.9% |
| 3 months | +27.2% | — | $1,272 | +2.1% |
| Year to date | +36.4% | — | $1,364 | +11.7% |
| 1 year | +10.3% | — | $1,103 | +12.4% |
| 3 years | +541.3% | +85.8% | $6,413 | +88.5% |
| 5 years | +475.8% | +41.9% | $5,758 | +76.0% |
Xeris Biopharma return by calendar year
| Year | XERS | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +36.4% | +11.7% | +24.7% |
| 2025 | +131.6% | +17.7% | +113.8% |
| 2024 | +44.3% | +24.9% | +19.4% |
| 2023 | +76.7% | +26.2% | +50.5% |
| 2022 | -54.6% | -18.2% | -36.4% |
| 2021 | -40.4% | +28.7% | -69.2% |
| 2020 | -30.2% | +18.4% | -48.6% |
| 2019 | -58.5% | +31.2% | -89.8% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: XERS financials
No forecast, no recommendation. This page describes Xeris Biopharma Holdings Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.